Further studies should be performed to fully uncover the implication of MSLN expression in CRC patients, specifically MSS patients, to improve the efficacy and availability of therapeutic options to a patient population that currently sees limited benefit beyond progression on the current standard of care treatment options. Here, MSLN is linked to colorectal carcinoma.